Canopy Growth Corporation
13
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
30.8%
4 terminated/withdrawn out of 13 trials
63.6%
-22.9% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants
Role: collaborator
The Pharmacodynamics of Cannabinoid-Caffeine Combinations
Role: collaborator
The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions
Role: collaborator
A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality
Role: lead
The Effects of CBD Isolate on Menstrual-Related Symptoms
Role: lead
CBD in Postmenopausal Women With Osteopenia
Role: lead
Canadian Registry for the Use of Spectrum Therapeutics Cannabis Products in Subjects With Chronic Pain
Role: lead
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants
Role: lead
Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity
Role: lead
CHI-907 CBD Extract and Experiences of Test Anxiety
Role: lead
A Randomized Controlled Test of the Effects of CHI-554 on Fear.
Role: lead
Investigation of the Efficacy and Safety of CHI-921 in Insomnia.
Role: lead
CHI-902 for Treatment of Social Anxiety Disorder
Role: lead
All 13 trials loaded